DEMO

Log In | Sign Up



Catalent

Selected Articles

2025-08-11
GlobeNewswire
mRNA Platform Strategic Business Analysis Report 2025 | Global Market to Reach $129.1 Billion by 2030 - Rising Infectious Diseases, Technological Advancements, and Pandemic Preparedness Drive Growth
2025-08-08
ETF Daily News
Head-To-Head Analysis: Exelixis (NASDAQ:EXEL) and Cadrenal Therapeutics (NASDAQ:CVKD)
2025-08-07
GlobeNewswire
U.S. Active Pharmaceutical Ingredients CDMO Market Report 2025-2030 | Competitive Analysis of Thermo Fisher Scientific, Novo Group, Cambrex, Piramal, Corden, Siegfried, Seqens, SK, Noramco, BSP
2025-08-05
PR Newswire UK
Cell Line and Membrane Market to Grow at 12.5% CAGR Through 2030
2025-08-05
GlobeNewswire
New Drug Approvals and their Contract Manufacture, 2025 Edition: How Global Issues Affect Pharma Manufacturers
2025-08-04
Pharmaceutical Technology
Manufacturing issues at Novo facility disrupt Regeneron drug review
2025-08-04
GlobeNewswire
Contract Manufacturing Market Forecast to 2030, with Case Studies of Thermo Fisher Scientific and Flextronics
2025-08-01
Biztoc.com
Regeneron's Pipeline Hit By Catalent Delays, But Dupixent Shines
2025-08-01
GlobeNewswire
Regeneron Reports Second Quarter 2025 Financial and Operating Results
2025-07-30
GlobeNewswire
Global Antibody Discovery Market to Observe Stupendous Growth at a CAGR of ~10% by 2032 | DelveInsight

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves biotechnology, pharmaceutical, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey. US1488061029 www.catalent.com